Independent Test of Vivo 45LS vs Trilogy and Astral Leakage and Tidal Volume Variation

“When comparing functions under the different lung conditions and varying levels of an imposed leak, the Vivo 45LS had a more dependable and desirable pattern of performance.”

Breas sponsored the attached independent study done by Jonathan Waugh PhD, RRT, RPFT, FAARC. The study’s aim was to evaluate the volume delivery characteristics and leak compensation of the Vivo 45LS, Trilogy Evo, and Astral 150 with regards to:

  • Tidal volume (TV) variation
  • Variation in delivered TV between 3 devices of the same ventilator model
  • The time to reach the set target volume

The Study Concludes:

  • The Vivo 45LS had the best overall performance with regard to the most accurate average tidal volume and the least variation in values.
  • When all levels of imposed leaks were considered, the Vivo 45LS had the lowest cumulative CV, indicating it was most stable and consistent in its output in the face of changing levels of leaks. This is a significant consideration. For example, a mean tidal volume of 500 mL that has a range of +/-10 mL is potentially safer than a mean tidal volume of 500 mL that has a range of +/- 50 mL.
  • The Astral 150 had the shortest time to reach the target volume criterion with the Vivo 45 having the second shortest time to reach the target volume.
  • The Trilogy Evo required the longest time to reach the target tidal volume criterion of +/- 5% of the set volume.
  • Too fast a time to reach the target volume may disturb sleep and too slow a time may impair ventilation.
  • Although the size of the ventilator was not part of the study, the Vivo 45LS is the smallest ventilator of the three models tested. Despite the small size of the ventilator, it can deliver an accurate target volume. When comparing functions under the different lung conditions and varying levels of an imposed leak, the Vivo 45LS had a more dependable and desirable pattern of performance.

HOT-HMV Study

Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation

Patrick B. Murphy, PhD1,2Sunita Rehal, MSc3Gill Arbane, BSc (Hons)1; et al

June 6, 2017.

Key Points

Question  Does the addition of home noninvasive ventilation to home oxygen therapy prolong time to readmission or death for patients with chronic obstructive pulmonary disease and persistent hypercapnia following a life-threatening exacerbation?

Findings  In this randomized clinical trial of 116 patients, the addition of home noninvasive ventilation significantly prolonged time to readmission or death from 1.4 months to 4.3 months.

Meaning  The addition of home noninvasive ventilation to home oxygen therapy may improve outcomes in patients with severe chronic obstructive pulmonary disease and persistent hypercapnia following hospital admission.